Regeneron’s Arcalyst Fails to Win U.S. Backing for GoutAnna Edney
Regeneron Pharmaceuticals Inc., the maker of the autoinflammatory drug Arcalyst, failed to win U.S. approval to expand the use of the medicine for patients undergoing gout treatments.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.